The case history is presented of a 32 year old black man who developed haemoptysis leading to pulmonary haemorrhage and bilateral pulmonary infiltrates. He was found to have Kaposi's sarcoma ofthe lung with no evidence of skin or endobronchial lesions. (Thorax 1995;50:98- Laboratory data on admission were white blood cell count of 9000 with normal differential count, haemoglobin 13-2 g/l, platelet count 31 000/mm', prothrombin time 11 seconds (control 12 seconds), partial thromboplastin time 40 seconds (control 36 seconds), D-dimer >2, fibrinogen 4-8 g/l, electrolytes normal, blood urea nitrogen 22-84 mmol/l, creatinine 353-6 gimollI and glucose 6.6 mmol/l.
The high incidence of Kaposi's sarcoma in renal transplant recipients suggests that immunosuppressive therapy may be responsible. Its frequency is influenced by the type of immunosuppression, increasing up to 500-fold in those treated with azathioprine and methylprednisone, and 1000-fold in cyclosporintreated patients.6 Corticosteroids affect the immune system in several ways, but their role in the development of Kaposi's sarcoma is unclear. 5 Cyclosporin is an effective immunosuppressant with known inhibitory effects on T helper cells. It is also associated with other malignancies such as skin cancer, lymphoma, and other lymphoproliferative malignancies. These tumours usually appear within a few months after commencing immunotherapy and usually regress after discontinuation of treatment. ' Ostlere et al have postulated that the imbalance in the immune system seen during post-transplant immunosuppression may be responsible for the increased circulation offactors with angiogenic properties, or alternatively the loss of molecules with an inhibitory effect on angiogenesis.5 This may contribute to the increased frequency of Kaposi's sarcoma seen in renal transplant patients.
Bencini et al reported Kaposi's sarcoma in 1 1 of 820 kidney transplant recipients (1 .3%), mainly in the skin with very few patients having widespread mucocutaneous, visceral, and lymphatic lesions. They also point out that Kaposi's sarcoma developed after a relatively short period of immunosuppression (6-40 months) in the patients treated with cyclosporin, suggesting that immunosuppression in the immediate post-transplant period may be an accelerating factor for the development of Kaposi's sarcoma in a population predisposed. 6 Shmueli et al have also reported an increased incidence of Kaposi's sarcoma among patients treated with cyclosporin compared with azathioprine. 7 Although the diagnosis was made before death in our patient, discontinuing the immunosuppressant treatment and initiating aggressive combination chemotherapy made no difference, although the duration of both these interventions was short. In some patients there have been reports of regression of Kaposi's sarcoma lesions when their immunosuppressive therapy was altered or discontinued.' Whilst Kaposi's sarcoma is increasingly described in the renal transplant population, it is not usually associated with fatal pulmonary haemorrhage and must be considered in this clinical setting. 
